Key result
Anticoagulants and antithrombotics lack extractable clinical outcomes due to a missing abstract.
Why the study?
Hospitalized and stable HF patients have an increased risk of thrombo-embolic events, making potential protection with anticoagulants and antithrombotics, particularly NOACs, of clinical interest.
Answers are grounded in this paper and cite their sources.
Central focus on anticoagulants and antithrombotics signals ongoing relevance; Level 5 data leaves specific outcomes open for higher-evidence trials.
Hospitalized and stable HF patients are both at increased risk of thrombo-embolic events, making the possibility of protection via the use of anticoagulants and/or antithrombotics attractive. The 2016 ESC guidelines on HF, do not recommend aspirin or anticoagulation in HF patients in SR, or any antiplatelet drugs in patients with HF without concomitant CAD. NOACs have a favourable safety profile and simplicity of use. This has led to interest in their use in HF. Secondary analyses showed that patients with HF with high cardiovascular risk and/or CAD may benefit from NOACs. However, these benefits in HF patients in SR were not confirmed in the large COMMANDER HF trial where rivaroxaban 2.5 mg twice daily did not reduce the primary endpoint (death from any cause, MI, stroke), nor achieve its primary safety outcome. In patients with HF in AF guidelines recommend an oral anticoagulant to prevent thrombo-embolism for all patients with paroxysmal or persistent/permanent AF and CHA2DS2 VASc ≥2, and for patients with HF and non-valvular AF, eligible for anticoagulation based on a CHA2DS2-VASc score, NOACs rather than warfarin should be considered.
No takes yet. Share an insight, caveat, or question.
Domienik‐Karłowicz et al. (2019) conducted a review in Heart Failure. Anticoagulants and antithrombotics (including NOACs such as rivaroxaban) vs. Warfarin or no anticoagulation was evaluated on Death from any cause, MI, or stroke (COMMANDER HF). Rivaroxaban twice daily did not reduce death, MI, or stroke in HF with sinus rhythm, whereas NOACs are recommended for HF with AF and CHA2DS2-VASc ≥2.
Synapse has enriched 10 related papers. Consider them for comparative context: